1993D0590 — EN — 27.10.1995 — 001.001 — 1
This document is meant purely as a documentation tool and the institutions do not assume any liability for its contents
►B COMMISSION DECISION
of 5 November 1993
for the purchase by the Community of foot-and-mouth disease antigens within the framework of
the Community action concerning reserves of foot-and-mouth disease vaccines
(93/590/EC)
(OJ L 280, 13.11.1993, p. 33)
Amended by:
Official Journal
Nopage date
►M1Commission Decision 95/471/EC of 26 October 1995 L 269 29 11.11.1995
NB: This consolidated version contains references to the European unit of account and/or the ecu, which from 1 January 1999
should be understood as references to the euro — Council Regulation (EEC) No 3308/80 (OJ L 345, 20.12.1980, p. 1) andCouncil Regulation (EC) No 1103/97 (OJ L 162, 19.6.1997, p. 1).
1993D0590 — EN — 27.10.1995 — 001.001 — 2
▼B
COMMISSION DECISION
of 5 November 1993
for the purchase by the Community of foot-and-mouth disease
antigens within the framework of the Community action concerning
reserves of foot-and-mouth disease vaccines
(93/590/EC)
THE COMMISSION OF THE EUROPEAN COMMUNITIES,
Having regard to the Treaty establishing the European Community,
Having regard to Council Decision 90/424/EEC of 26 June 1990 on
expenditure in the veterinary field(1), as last amended by Commission
Decision 93/439/EEC (2), and in particular Article 14 thereof,
Having regard to Council Decision 91/666/EEC of 11 December 1991
establishing Community reserves of foot-and-mouth diseasevaccines(
3), and, in particular, Articles 5 and 7 thereof,
Whereas, in conformity with Decision 91/666/EEC, the purchase of
antigens is a part of the Community action to establish Communityreserves of foot and mouth disease vaccines;
Whereas the Commission has issued a call for tenders for the supply of
antigens;
Whereas the Commission has examined the submitted tenders taking
into account the following factors:
— the technical requirements of Annex II to Decision 91/666/EEC and
other criteria mentioned in Article 5 of that Decision,
— that some establishments are unable to supply the full number of
doses of some antigens,
— the need for the producing establishment to be in full conformity
with the guidelines for good manufacturing practices (GMP);
Whereas the Commission has selected Rhône-Mérieux to supply five
million doses of each of subtypes A
5,A22,O1European strain and O1Middle East strain as a first step; whereas the establishments which willsupply the other strains in Annex I to Decision 91/666/EEC will bedecided after a further call for tenders;
Whereas financial provisions should be made to allow the Commission
topurchase these strains fro m Rhône-Mérieux;
Whereas, under the provisions of Article 7 of Decision 91/666/EEC, it
is necessary to lay down the rules for the distribution of antigenreserves between the antigen banks, nominated in Article 1 of the saidDecision;
Whereas it is appropriate that each strain should be divided equally
between two banks; whereas the strains stored in each bank should berelated geographically to the most likely area of risk;
Whereas in accordance with Article 40 of Council Decision 90/
424/EEC, checks provided for in Articles 8 and 9 of Council Regulation(EEC) No 729/70 of 21 April 1970 concerning the financing of thecommon agricultural policy (
4) shall apply; whereas, moreover, certain
particular provisions should be made;
Whereas the measures provided for in this Decision are in accordance
with the opinion of the Standing Veterinary Committee,
(1) OJ NoL 224, 18. 8. 1990, p. 19.
(2) OJ NoL 203, 13. 8. 1993, p. 34.
(3) OJ NoL 368, 31. 12. 1991, p. 21.
(4) OJ NoL 94, 28. 4. 1970, p. 13.
1993D0590 — EN — 27.10.1995 — 001.001 — 3
▼B
HAS ADOPTED THIS DECISION:
Article 1
1. The Community shall purchase five million doses of each of the
following strains of foot-and-mouth disease antigen:
—A5European,
—A22Middle East,
—O1Middle East,
—O1European,
up to a maximum cost of ECU 4 065 million.
2. The antigen mentioned in paragraph 1 shall be supplied by Rhône-
Mérieux, Pirbright Laboratory, Ash Road, Surrey, United Kingdom.
Article 2
1. To meet the objectives of Article 1, the Commission shall
conclude a contract, in the name of the European Community, withRhône-Mérieux.
2. The Director General of Directorate General for Agriculture shall
be authorized to sign the contract on behalf of the Commission of theEuropean Communities.
3. Payment toRhône-Mérieux shall be made in acco rdance with the
terms of the contract provided for in paragraph 1.
▼
M1
Article 3
The antigen shall be divided between the three antigen banks as
follows:
(a) The Institute for Animal Health, Pirbright: 2,5 million doses of each
ofO1European Strain and A5European strain;
(b) lZP, Brescia: 2,5 million doses of each of O1Middle East strain and
A22;
(c) LNPB, Lyon: 2,5 million doses of each of O1Middle East strain,
A22,O1European strain and A5,O1European strain.
▼B
Article 4
This Decision is addressed to the Member States.